MAPK1 and glomerulosclerosis: An aberrant effect of ERK was also confirmed in proteinuric glomerular diseases, such as diabetic nephropathy, glomerulosclerosis, and nephritic syndrome (Das et al., 2019; Pan et al., 2025; Zhang et al., 2025).